



CURRICULUM VITAE ABREVIADO (CVA)

Date of the CVA

16/02/2026

Part A. PERSONAL INFORMATION

First name	Mariana		
Family name	Landin Pérez		
Gender (*)	Female	Birth date (dd/mm/yyyy)	13/10/1963
Social Security, Passport, ID number			
		URL Web	
Researcher's identification number	Researcher ID	AAA-5880-2019	
	Scopus Author ID	9739619000	
	ORCID	0000-0002-2835-8958	

A.1. Current position

Position	Full Professor		
Initial date	September 2023		
Institution	University of Santiago		
Department/Center	Dpt. Pharmacology, Pharmacy and Pharmaceutical Technology/Faculty of Pharmacy		
Country	Spain	Teleph. number	+34 8818 15044
Key words	Artificial intelligence tools, pharmaceutical formulations, drug delivery systems, hydrogels, aerogels, microparticles, nanoparticles		

A.2. Previous positions (research activity interruptions, indicate total months)

Period	Position/Institution/Country/Interruption cause
1998-2023	Lecturer at USC/Spain
11/1997-2/1998	Assistant Profesor at USC/Spain
9/1996-11/1997	Postdoctoral Researcher at USC/Spain
2/1996-9/1996	Regulatory Affairs Officer in Laboratorios Instituto Farmacológico Español
1993-1995	Research Fellow at University of Bradford (UK)
1991-1992	Postdoctoral Researcher at USC/Spain

A.3. Education

PhD, Licensed, Graduate	University/Country	Year
PhD in Pharmacy	University of Santiago de Compostela (USC)	1991
Degree in Pharmacy	Faculty of Pharmacy (USC)	1986

Part B. CV SUMMARY (max. 5000 characters, including spaces)

[Mariana Landin Pérez](#) is full Professor in Pharmacy and Pharmaceutical Technology at Universidad de Santiago de Compostela and Specialist in Industrial and Galenic Pharmacy. Prof. Landin has been actively involved in research for over three decades, contributing significantly to the advancement of pharmaceutical science. She has a background (PhD in Pharmacy) and broad experience in the areas of pharmaceutical material science and processing, such as raw materials characterization and variability, or scale-up process. She has also extensive experience in the design and evaluation of biomaterials for tissue engineering, and immediate and controlled drug delivery systems.

Since 2009, her interest has been focused on the applicability of Artificial Intelligence tools (Artificial Neural Networks, Neurofuzzylogic and genetic programming) for modeling biological and technological process to their better understanding or to a rational design of



new and/or better dosage forms. She has been a pioneer in the field of AI applied to Pharmacy, and also to biotechnological process through her multidisciplinary collaborations. She has authored over 100 [peer-reviewed publications](#) in top-tier scientific journals in her field, as *Advanced Healthcare Materials*, *International Journal of Pharmaceutics*, and *European Journal of Pharmaceutics and Biopharmaceutics*, etc. Her work has been cited over 3,200 times. Her h-index is 35 and i10 h-index is 78 in Google Scholar (01/2024) demonstrating high impact within the field. Her work has attracted the attention of pharmaceutical and biotechnological companies, which has led her to be scientific advisor of some of them such as [Gistem Research](#) (Spain) or Pinar Biotech Co., Ltd (Iran). Prof. Landin has demonstrated a strong commitment to research and innovation through her participation and leadership of several projects. She has actively contributed to 32 [national and international research projects and contracts](#). Notably, since 2009, she has assumed the role of principal investigator in seven instances, showcasing her leadership capabilities within the research domain.

Prof. Landin's contributions to pharmaceutical science have been recognized through various recent awards (Julian Suárez Freire in 2023; ITALFARMACO-[SEIOMM](#) in 2022). She is also a member of several prestigious scientific societies, including [SPLC-CRS](#), [EUFEPS](#) or [SEFIG](#) of which she was a member of the Board as secretary.

She has primarily conducted her research within the [I+D Farma research group](#). However, she is integrated with various other research national networks, including the USC Materials Institute ([iMATUS](#)) or the Health Research Institute of the Santiago de Compostela ([IDIS](#)), and actively participates in international consortia such as the [Multipolar Centre of Valorization](#) or [Aerogel Cost](#). This diverse engagement reflects her commitment to undertaking multidisciplinary and international research endeavours. With a passion for international collaboration, Prof Landin has accumulated 3.7 years across research stays in diverse global institutions, including a year-long sabbatical at the University of Utrecht (2010-11), funded by the Salvador de Madariaga Program (MEC), and a postdoctoral stay (1994-1995) at the University of Bradford, supported by the EU Human Capital and Mobility – Individual Fellowship.

Beyond research, actively contributed to the organization of more than a dozen international and national scientific events. Additionally, she possesses expertise in human resources and project evaluations for Research Agencies in Spain, Norway, the Netherlands, and Poland.

Prof. Landin is also a dedicated educator and mentor. She has supervised numerous master, doctoral and postdoctoral students, fostering their professional development and encouraging their contributions to the field. Several of her doctoral students (all hold International Mention Ph. D.) today occupy significant roles in research within the healthcare, academic, or industry sectors. They assume positions of responsibility, contributing their expertise to advance knowledge and innovation in their respective fields. She has also been Coordinator of the Erasmus Program interchanging students with several countries as Belgium, Italy, Greece or Georgia.

For the past seven years, Prof. Landin has actively participated in teaching and curriculum development, serving as the coordinator of the Master's Degree in Drug Research and Development (USC). In this role, she plays a pivotal part in shaping the future of pharmaceutical research by training the next generation of scientists.

She has been a speaker at various university orientation events and scientific outreach courses, actively promoting academic culture. Her commitment to scientific dissemination underscores her desire for making academia accessible and engaging.

Part C. RELEVANT MERITS (*sorted by typology*)

C.1. Publications. Selection of recent publications related to the project ([Link to complete list](#))

1. **Open Access scientific paper.** H. Rouco, M. Permy, F. Muñoz, J.A. Vázquez, J.R. Caeiro, M. Landin. P. Diaz-Rodriguez (5/6) (2025) Micelle into gel thermosensitive intra-articular hydrogels for osteoarthritis management. *J. Control Release.* 381, 113639 <https://doi.org/10.1016/j.jconrel.2025.113639> (IF=10.5; Q1, D1, 12/354 in Pharmacology & Pharmacy section (SCIE)).
2. **Open Access scientific paper.** R. Martinez-Borrajo, P. Diaz-Rodriguez, M. Landin. (3/3) (2024) Engineering mannose-functionalized nanostructured lipid carriers by sequential design using hybrid artificial intelligence tools. *Drug Deliv. and Transl. Res* <https://doi.org/10.1007/s13346-024-01603-z> (IF=5.7; Q1, 30/354 in Pharmacology & Pharmacy section (SCIE)).
3. **Open Access review.** C Illanes-Bordomas, M Landin, CA García-González. (2/3, AC) (2023) Aerogels as Carriers for Oral Administration of Drugs: An Approach towards Colonic Delivery. *Pharmaceutics* 15 (11), 2639. D.O.I.: [10.3390/pharmaceutics15112639](https://doi.org/10.3390/pharmaceutics15112639). (IF=5.4; Q1, 50/278 in Pharmacology & Pharmacy section (SCIE)).
4. **Open Access scientific paper.** L. García del Rio, P. Diaz-Rodriguez, G.K. Pedersen et al. (5/5) (2022) Sublingual boosting with a novel mucoadhesive thermogelling hydrogel following parenteral CAF01 priming as a strategy against chlamydia trachomatis. *Advanced Healthcare Materials.* 2102508, 1-9i. D.O.I.: [10.1002/adhm.202102508](https://doi.org/10.1002/adhm.202102508) (**Multidisciplinary & International collaboration**; IF=10; Q1, D1, 4/45 in Materials Science, Biomaterials section (SCIE); cited Scopus 7 & Google Scholar 7)
5. **Open Access scientific paper.** P. Diaz-Rodriguez, C. Mariño, J.A. Vázquez et al. (5/5). (2021) Targeting joint inflammation for osteoarthritis management through stimulus-sensitive hyaluronic acid based intra-articular hydrogels. *Materials Science and Engineering: C.* 128, 112254. D.O.I.: [10.1016/j.msec.2021.112254](https://doi.org/10.1016/j.msec.2021.112254) (**Multidisciplinary & National collaboration**; IF=8.457; Q1, 8/45 in Materials Science, Biomaterials section (SCIE); cited Scopus 17 & Google Scholar 23)
6. **Open Access scientific paper.** L. Garcia-del Rio, P. Diaz-Rodriguez, M. Landin (3/3) (2021) Design of novel orotransmucosal vaccine-delivery platforms using artificial intelligence. *European Journal of Pharmaceutics and Biopharmaceutics.* 159, 36-43. D.O.I.: [10.1016/j.ejpb.2020.12.018](https://doi.org/10.1016/j.ejpb.2020.12.018) (IF=5.589; Q1, 60/279 in Pharmacology & Pharmacy section (SCIE); cited Scopus 7 & Google Scholar 9)
7. **Open Access scientific paper.** J Sendon-Lago, LG Rio, N Eiro et al. (9/9) (2021) Tailored hydrogels as delivery platforms for conditioned medium from mesenchymal stem cells in a model of acute colitis in mice. *Pharmaceutics* 13 (8), 1127. D.O.I.: [10.3390/pharmaceutics13081127](https://doi.org/10.3390/pharmaceutics13081127) (**Multidisciplinary & National collaboration**; IF=8.457; Q1, 39/279 in Pharmacology & Pharmacy section (SCIE); cited Scopus 7 & Google Scholar 14)
8. **Open Access scientific paper.** L Garcia-del Rio, P Diaz-Rodriguez, M Landin. (3/3) (2020) New tools to design smart thermosensitive hydrogels for protein rectal delivery in IBD. *Materials Science and Engineering: C* 106, 110252. D.O.I.: [10.1016/J.MSEC.2019.110252](https://doi.org/10.1016/J.MSEC.2019.110252) (IF= 7.328; Q1, (7/41) Materials Science, Biomaterials section (SCIE); cited Scopus 22 & Google Scholar 25)
9. **Scientific paper.** H. Rouco, P. Diaz-Rodríguez, S. Rama-Molinos et al. (5/5) (2018). Delimiting the Knowledge Space and the Design Space of Nanostructured Lipid Carriers through Artificial Intelligence Tools. *International Journal of Pharmaceutics.* 553 (1-2) 523-530. D.O.I.: [10.1016/J.IJPHARM.2018.10.058](https://doi.org/10.1016/J.IJPHARM.2018.10.058) (IF= 4.213; Q1, 44/267 in Pharmacology & Pharmacy section (SCIE); cited Scopus 24 & Google Scholar 29)
10. **Scientific paper.** R. Rodríguez Dorado, M. Landin, A. Altai et al. (2/6) (2018). A novel method for the production of core-shell microparticles by inverse gelation optimized with artificial intelligent tools. *International Journal of Pharmaceutics.* 538 (1-2) 97-104. D.O.I.: [10.1016/J.IJPHARM.2018.01.023](https://doi.org/10.1016/J.IJPHARM.2018.01.023) (**International collaboration**; IF=4.213; Q1, 44/267 in Pharmacology & Pharmacy section (SCIE); cited Scopus 26 & Google Scholar 29)

C.2. Congress

1. **International Flash oral communication & Póster.** M. Landin, L. Costa, N. Eiro, M. Fraile, A. Vaca, J. Sendon-Lago, L. O. Gonzalez, T. Sanchez, M. López-Peña, M. Permuy, P. Díaz-Rodríguez, L. Garcia-del Rio, F. J. Vizoso. Complete Dentin-Pulp Repair with hUCESC Secretome in hydrogels: Preclinical Evidence of a Cell-Free Strategy, *XVI Spanish-Portuguese Conference on Controlled Drug Delivery*. Albacete, España. 14-16/1/2026.
2. **International Flash oral communication & Póster.** M. Landin, R. Rodríguez-Dorado, P. Del Gaudio. From trial-and-error to genetic algorithms for the formulation of microparticles. A methodological revolution, *European Federation of Pharmaceutical Science (EUFEPS) Annual Meeting 2023*: at the edge of Europe and Science. Lisbon, Portugal. 31/5-2/6/2023.
3. **National oral communication & award** R. Martínez-Borrajo, E. Bayon-Fernandez, José Ramón Caeiro Rey, M. Landin, P. Diaz-Rodriguez Desarrollo de nanopartículas de administración local que permitan reducir la progresión de la osteoartritis. *XXVI Sociedad Española de Investigación Ósea y del Metabolismo Mineral*. Madrid (Spain) 5-7/10/2022
4. **International oral communication** L. García del Rio, M. Landin. Thermogelling and mucoadhesive hydrogels as sublingual boosters for obtaining mucosal immunity. *European Network of Vaccine Aduvants (ENOVA) Workshop*, Geneve, Italy, 19-20/09/2021.

C.3. Research projects.

Selection of projects and contracts related to the research line of the project (design of hidrogels, formulations of poor soluble drugs, AI, tissue engineering. In all of them M Landin is the PI. ([Link to complete list of projects of M.Landin](#))

1. **National Oriented Research Grant: Avances en aerogeles para aplicaciones biomédicas a través de soluciones sostenibles y herramientas de inteligencia artificial (ECOAEROGEL2HEAL)**. Financial support: Spanish Government (PID2023-151340OB-I00). USC 190000 € M. Landin & CA García-Gonzalez (PIs), Period: 01/09/2024-29/08/2027.
2. **International EU Basic Research Grant: IBEROS+. Instituto de Biofabricación en Red para el Envejecimiento+ Saludable**. Financial support: EU POCTEP Program (937_IBEROSmais_1_E). Consortium: USC, UVigo, Instituto Superior de Engenharia do Porto, Fundación Biomédica Galicia Sur, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, IBONELAB SL; BFlow, Laboratório Ibérico Internacional de Nanotecnologia; Grupo tecnológico ARBINOVA S.L., Comunidad Autónoma de Galicia-Consellería de Sanidad-Servicio Gallego de Salud, Intelligent Lab on Fiber Lda- iLoF. USC 265.109,21 €. M Landin (PI), Period: 01/07/2023-30/06/2026.
3. **National Oriented Research Grant: Engineering of aerogels for advanced biomedical uses (BIOAEROGEL2HEAL)**. Financial support: Spanish Government (PID2020-120010RB-I00). USC 133.100 € M. Landin & CA García-Gonzalez (PIs), Period: 01/09/2021-01/09/2024.
4. **International EU Development & Translational Research Grant: CVMAR+i**. Financial support: EU POCTEP Program (0302_CVMAR_I_1_P).; Consortium: USC, Bialactis Biotech, SL, CIIMAR, Celtaiga Extract S.L., Developbiosystem S.L., Universidade do Minho, FEUP, ARBINOVA SLU (BETA), IIM-CSIC IUVENOR LAB S.L., Improveat, Lda, INL, Intervir Mais, CETMAR, SARSPEC, Smart Innovation Lda, Stematters, Biotecnologia e Medicina Regenerativa SA, UVIGO. USC 111.479,97 €; M. Landin (PI); Period: 01/10/2015-30/09/2019;

C.4. Contracts, technological or transfer merits,

1. **Contract: Design, production, and supply of 10 units of 10 ml of thermosensitive hydrogel, packaged and autoclaved and characterized**. Financial support: Uterine Stem Cell Research Foundation ([FICEMU](#)) (Spain); 3.811,51 €, M. Landin y P. Diaz-Rodriguez (IPs); Period: 06/2021-04/2022.